Bridgewater Associates LP Has $38.01 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Bridgewater Associates LP boosted its stake in United Therapeutics Co. (NASDAQ:UTHR) by 74.4% during the fourth quarter, Holdings Channel reports. The institutional investor owned 107,730 shares of the biotechnology company’s stock after buying an additional 45,975 shares during the period. Bridgewater Associates LP’s holdings in United Therapeutics were worth $38,011,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of UTHR. Cerity Partners LLC grew its position in shares of United Therapeutics by 30.4% in the fourth quarter. Cerity Partners LLC now owns 11,588 shares of the biotechnology company’s stock valued at $4,098,000 after purchasing an additional 2,702 shares during the last quarter. Milestone Asset Management LLC boosted its stake in United Therapeutics by 56.5% in the 4th quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company’s stock valued at $1,014,000 after purchasing an additional 1,037 shares during the period. Korea Investment CORP grew its holdings in United Therapeutics by 6.2% in the 4th quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company’s stock valued at $13,863,000 after buying an additional 2,300 shares in the last quarter. Janney Montgomery Scott LLC increased its position in United Therapeutics by 9.1% during the 4th quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company’s stock worth $3,326,000 after buying an additional 789 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in shares of United Therapeutics by 35.4% during the third quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock worth $68,999,000 after buying an additional 50,291 shares in the last quarter. 94.08% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several research reports. HC Wainwright restated a “buy” rating and issued a $425.00 price target on shares of United Therapeutics in a research note on Thursday, February 27th. UBS Group increased their target price on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a research report on Wednesday, January 8th. Finally, StockNews.com cut shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $388.25.

United Therapeutics Trading Up 1.1 %

NASDAQ UTHR opened at $284.31 on Tuesday. The firm’s 50 day simple moving average is $321.83 and its 200 day simple moving average is $350.58. The firm has a market capitalization of $12.77 billion, a price-to-earnings ratio of 12.49, a P/E/G ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a 1 year low of $230.39 and a 1 year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million during the quarter, compared to analysts’ expectations of $734.74 million. During the same period in the prior year, the company earned $4.36 earnings per share. On average, equities research analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Raymond Dwek sold 4,000 shares of the stock in a transaction on Monday, April 7th. The stock was sold at an average price of $284.55, for a total value of $1,138,200.00. Following the completion of the transaction, the director now directly owns 1,750 shares in the company, valued at approximately $497,962.50. This represents a 69.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Tommy G. Thompson sold 2,500 shares of the business’s stock in a transaction on Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the sale, the director now owns 8,480 shares in the company, valued at $2,703,424. This represents a 22.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 77,500 shares of company stock worth $26,994,480 in the last ninety days. 11.90% of the stock is owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.